Pharmaceutical composition for treating or preventing heart failure and application of pharmaceutical composition

A technology of heart failure and composition, which is applied in the combined drug for the treatment or prevention of heart failure and its application field, which can solve the problems of large side effects and insufficient curative effect, and achieve the effect of expanding the scope of medication

Inactive Publication Date: 2021-08-06
HEFEI KNATURE BIO PHARM CO LTD +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The technical problem to be solved by the present invention is the technical problem that anti-heart failure drugs in the prior art have insufficient curative effect and relatively large side effects in the treatment of heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating or preventing heart failure and application of pharmaceutical composition
  • Pharmaceutical composition for treating or preventing heart failure and application of pharmaceutical composition
  • Pharmaceutical composition for treating or preventing heart failure and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Effect of combined application of NAD and sartans on left ventricular ejection fraction

[0025] NAD (nicotinamide adenine dinucleotide) was combined with 4 kinds of sartan drugs (losartan LS, valsartan XS, irbesartan EB or olmesartan medoxomil AM), and the rats were treated according to Table 1 Carry out grouping and administration, and observe the influence on ejection fraction.

[0026] Table 1 Grouping and dosing regimen of rats

[0027]

[0028] After 12 weeks of administration, the ejection fraction of each group was measured, and the results are shown in figure 1 . Compared with WKY rats, the ejection fraction of SHR rats in the model group decreased significantly. Compared with the model group, after 12 weeks of administration, the ejection fractions of all other administration groups were significantly increased (P<0.01). Comparing the administration groups, the NAD+LS group had a significant difference (P<0.05) compared with the NAD group or t...

Embodiment 2

[0029] Example 2 Effects of combined application of NAD and olmesartan medoxomil on left ventricular weight coefficient

[0030] NAD was combined with olmesartan medoxomil AM, and the rats were grouped and administered according to Table 2, and the influence on the left ventricular weight coefficient was observed.

[0031] Table 2 Grouping and dosing regimen of rats

[0032]

[0033] After 12 weeks of administration, the left ventricular weight coefficient of each group was determined (see figure 2 ). Compared with the WKY group, the weight coefficient of the left ventricle of SHR rats was significantly increased (P<0.01), the test drug group could reduce the left ventricle weight coefficient of the model rats to varying degrees, and the NAD+AM group had a significant reduction effect (P<0.01) , where the combination of AM and NAD showed a synergistic effect (**P<0.01, compared with the WKY group; #P<0.05, ##P<0.01, compared with the single use group).

Embodiment 3

[0034] Example 3 Effect of combined application of NAD and olmesartan medoxomil on myocardial mitochondrial membrane potential and ATP level

[0035] NAD was used in combination with olmesartan medoxomil AM, and the rats were grouped and administered according to Table 3, and the effects on myocardial mitochondrial membrane potential and ATP levels were observed.

[0036] Table 3 Grouping and dosing regimen of rats

[0037]

[0038] After 12 weeks of administration, the myocardial mitochondrial membrane potential and ATP levels were measured in each group (see image 3 ). Compared with WKY group, myocardial mitochondrial membrane potential of SHR rats decreased significantly (P<0.01), and ATP level also decreased. The NAD+AM group can significantly restore the myocardial mitochondrial membrane potential of SHR rats, and at the same time increase the ATP level. Compared with the AM group or NAD alone, the combined use of AM and NAD has a synergistic effect (**P<0.01, compa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of pharmaceutical compositions, and particularly provides a pharmaceutical composition for treating or preventing heart failure,. The pharmaceutical composition comprises NAD and olmesartan, olmesartan medoxomil, olmesartan derivatives and / or olmesartan medoxomil derivatives thereof. The NAD has the Chinese name of nicotinamide adenine dinucleotide, and is called coenzyme I for short. The mass ratio of the NAD to the olmesartan, olmesartan medoxomil, olmesartan derivative and / or the olmesartan medoxomil derivative and the olmesartan medoxomil or the olmesartan medoxomil derivative is (1-100): (1-100). The pharmaceutical composition has the effect of synergistically preventing or treating the heart failure, and especially has clinical guiding significance for preventing or treating the heart failure with reserved ejection fraction.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to a combination medicine for treating or preventing heart failure and its application. Background technique [0002] Heart failure (HF) refers to a pathophysiological state in which abnormal cardiac function causes the pumping volume of the heart to fail to meet the needs of tissue metabolism. The etiology is caused by any reason such as overloading of the heart, the myocardium itself, and restriction of diastole. The initial myocardial injury leads to low structural function and progressive onset. At present, with the aging of my country's population, the incidence of hypertension and coronary heart disease is increasing year by year, leading to an increase in the prevalence of heart failure. [0003] Heart failure is not an independent disease, but the end stage of the development of heart disease. The vast majority of heart failures begin with left heart f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7084A61K31/4178A61P9/04
CPCA61K31/7084A61K31/4178A61P9/04
Inventor 王伟王康林王磊戈晓爱王涛
Owner HEFEI KNATURE BIO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap